A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Amber K WeinerAlexander B RadaouiMatthew TsangDaniel MartinezSimone SidoliKarina L ConkriteAlberto DelaidelliApexa ModiJo Lynne RokitaKhushbu PatelMaria V LaneBo ZhangChuwei ZhongBrian M EnnisDaniel P MillerMiguel A BrownKomal S RathiPichai RamanJennifer PogorilerTricia BhattiBruce PawelTina Glisovic-AplencBeverly TeicherStephen W EricksonEric Jay EarleyKristopher R BossePoul H SorensenKateryna KrytskaYael P MosseKarin E HavenithFrancesca ZammarchiPatrick H van BerkelMalcolm A SmithBenjamin A GarciaJohn M MarisSharon J DiskinPublished in: bioRxiv : the preprint server for biology (2023)
silencing in neuroblastoma cells results in cellular differentiation ADCT-701, a DLK1-targeting antibody-drug conjugate, shows potent and specific cytotoxicity in DLK1-expressing neuroblastoma preclinical models.